Results 11 to 20 of about 60,331 (176)

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

Generating a Novel Bispecific Nanobody to Enhance Antitumor Activity

Pharmaceutical Fronts, 2020
Tumor cells express high levels of human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor 2 (VEGFR2), which are closely related to their proliferation and survival. Cancer treatments that target a single signaling
Qiuhan Ge, Tianyuan Sun, Yanlin Bian, Xiaodong Xiao, Jianwei Zhu   +4 more
doaj   +1 more source

A bivalent cyclic RGD–siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts

Drug Delivery, 2021
The vascular endothelial growth factor receptor 2 (VEGFR2) is considered to be a pivotal target for anti-tumor therapy against angiogenesis of non-small cell lung cancer (NSCLC).
Lumin Liao, Bohong Cen, Guoxian Li, Yuanyi Wei, Zhen Wang, Wen Huang, Shuai He, Yawei Yuan, Aimin Ji   +8 more
doaj   +1 more source

VEGFR2 inhibition hampers breast cancer cell proliferation via enhanced mitochondrial biogenesis

Cancer Biology & Medicine, 2021
Objective: Vascular endothelial growth factor (VEGF), apart from its predominant roles in angiogenesis, can enhance cancer cell proliferation, but its mechanisms remain elusive.
Hao Ni, Min Guo, Xuepei Zhang, Lei Jiang, Shuai Tan, Juan Yuan, HuanhuanL Cui, Yanan Min, Junhao Zhang, Susanne Schlisio, Chunhong Ma, Wangjun Liao, Monica Nister, Chunlin Chen, Shuijie Li, Nailin Li   +15 more
doaj   +1 more source

Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer

OncoImmunology, 2017
Interferon-α (IFNα) has multiple antitumor effects including direct antitumor toxicity and the ability to potently stimulate both innate and adaptive immunity.
Zhaoting Li, Yijia Zhu, Chenchen Li, Ryan Trinh, Xueyan Ren, Fumou Sun, Youfu Wang, Pengzhao Shang, Tong Wang, Min Wang, Sherie L. Morrison, Juan Zhang   +11 more
doaj   +1 more source

Membrane-associated RING ubiquitin ligase RNF-121 and advancement of cancer [PDF]

Cellular, Molecular and Biomedical Reports
Exploration of E3 ubiquitin ligases as potential therapeutic targets has been ongoing for two to three decades. Various chemicals and drugs have been developed to either upregulate or inhibit the activity of E3 ligases, aiming to mitigate several ...
Somesh Roy
doaj   +1 more source

Paeonol Promotes Reendothelialization After Vascular Injury Through Activation of c-Myc/VEGFR2 Signaling Pathway

Drug Design, Development and Therapy, 2023
Yang Wang,1,* Zheng Wang,1,* Xiao Wu,1,* Song Zhu,2,* Qiru Guo,1 Zhong Jin,1 Zixian Chen,3 Delai Zhang,2 Wangming Hu,1 Huan Xu,1 Liangqin Shi,1 Lan Yang,1 Yong Wang1 1College of Basic Medicine, Chengdu University of Traditional Chinese ...
Wang Y, Wang Z, Wu X, Zhu S, Guo Q, Jin Z, Chen Z, Zhang D, Hu W, Xu H, Shi L, Yang L, Wang Y   +12 more
doaj  

Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model. [PDF]

PLoS Computational Biology, 2015
Matrix-binding isoforms and non-matrix-binding isoforms of vascular endothelial growth factor (VEGF) are both capable of stimulating vascular remodeling, but the resulting blood vessel networks are structurally and functionally different.
Lindsay Wendel Clegg, Feilim Mac Gabhann
doaj   +1 more source

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

OncoImmunology, 2018
VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention.
Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, Lilli Podola, Tobias Friedrich, Heinz Lubenau, Marco Springer, Sébastien Wieckowski, Klaus M. Breiner, Gerd Mikus, Markus W. Büchler, Anne-Valerie Keller, Ruhan Koc, Christoph Springfeld, Phillip Knebel, Mariana Bucur, Lars Grenacher, Walter E. Haefeli, Philipp Beckhove   +18 more
doaj   +1 more source

Role of VEGF-VEGFR2 signaling pathway in psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2022
VEGF-VEGFR2 signaling pathway plays an important role in the course of psoriasis. Binding of VEGF to VEGFR2 induces receptor dimerization and autophosphorylation at multiple tyrosine sites, promoting the activation of the downstream ERK1/2 signaling ...
Xiaomei LUO, Zhiyong CHENG, Xiaoqun HAN, Yong WANG   +3 more
doaj   +1 more source